The Oncologist, Vol. 12, No. 1, 38-50, January 2007; doi:10.1634/theoncologist.12-1-38
© 2007 AlphaMed Press
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Richard M. Goldberga,
Mace L. Rothenbergb,
Eric Van Cutsemc,
Al B. Benson, IIId,
Charles D. Blankee,
Robert B. Diasiof,
Axel Grotheyg,
Heinz-Josef Lenzh,
Neal J. Meropoli,
Ramesh K. Ramanathanj,
Carlos H. Roberto Becerrak,
Rita Wickhaml,
Delma Armstrongm,
Carol Vielen
a Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;
b Division of Hematology/Medical Oncology, Vanderbilt University, Nashville, Tennessee, USA;
c Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium;
d Division of Hematology/Oncology, Northwestern University, Chicago, Illinois, USA;
e Oregon Health & Science University Cancer Institute, Portland, Oregon, USA;
f Division of Hematology/Oncology, University of Alabama School of Medicine, Birmingham, Alabama, USA;
g Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA;
h Division of Medical Oncology, University of Southern California, Los Angeles, California, USA;
i Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA;
j Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA;
k Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA;
l Department of Adult Health Nursing, Rush University Medical Center, Chicago, Illinois, USA;
m University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA;
n Department of Nursing at University of California San Francisco Medical Center, San Francisco, California, USA
Key Words. Colorectal cancer • Chemotherapy • Biologic therapy
Correspondence:
Mace L. Rothenberg, M.D., 777 Preston Building, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6307, USA. Telephone: 615-936-1796; Fax: 615-343-7602; e-mail: mace.rothenberg{at}vanderbilt.edu
New agents for the treatment of metastatic colorectal cancer have extended median overall survival to more than 20 months, an increase that has changed the view of advanced colorectal cancer from an acute to a chronic condition. This article proposes a shift in treatment strategy from the concept of successive "lines" of therapy, in which chemotherapy is continued until disease progression, to that of a continuum of care, in which the use of chemotherapy is tailored to the clinical setting and includes switching chemotherapy prior to disease progression, maintenance therapy, drug "holidays," and surgical resection of metastases in selected patients. In this approach, the distinction between lines of therapy is no longer absolute. This represents a paradigm shift in the management of metastatic colorectal cancer to that of a continuum of care approach that includes individualized planning, in which patients are given the opportunity to benefit from exposure to all active agents and modalities while minimizing unnecessary treatment and toxicity, with the ultimate goal of improving survival as well as quality of life.
This article has been cited by other articles:

|
 |

|
 |
 
M. W. Saif, A. Choma, S. J. Salamone, and E. Chu
Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes
J Natl Cancer Inst,
November 18, 2009;
101(22):
1543 - 1552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Y. Zafar, J. E. Marcello, J. L. Wheeler, K. L. Rowe, M. A. Morse, J. E. Herndon II, and A. P. Abernethy
Longitudinal Patterns of Chemotherapy Use in Metastatic Colorectal Cancer
J. Oncol. Pract,
September 1, 2009;
5(5):
228 - 233.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology,
September 1, 2009;
1(2):
55 - 68.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Van Cutsem, R. Labianca, G. Bodoky, C. Barone, E. Aranda, B. Nordlinger, C. Topham, J. Tabernero, T. Andre, A. F. Sobrero, et al.
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
J. Clin. Oncol.,
July 1, 2009;
27(19):
3117 - 3125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist,
May 1, 2009;
14(5):
478 - 488.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Dallas, L. Xia, F. Fan, M. J. Gray, P. Gaur, G. van Buren II, S. Samuel, M. P. Kim, S. J. Lim, and L. M. Ellis
Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition
Cancer Res.,
March 1, 2009;
69(5):
1951 - 1957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grothey
Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective
Statistical Methods in Medical Research,
October 1, 2008;
17(5):
529 - 535.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
Ann. Onc.,
October 1, 2008;
19(10):
1720 - 1726.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. H. O'Neil and R. M. Goldberg
Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
Oncologist,
October 1, 2008;
13(10):
1074 - 1083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Cohen, C. J.A. Punt, N. Iannotti, B. H. Saidman, K. D. Sabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, et al.
Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol.,
July 1, 2008;
26(19):
3213 - 3221.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Harrington and T. J. Smith
The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?"
JAMA,
June 11, 2008;
299(22):
2667 - 2678.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by AlphaMed Press.
|
|